Literature DB >> 16387822

Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk.

D P Chew1, D L Bhatt, A M Lincoff, K Wolski, E J Topol.   

Abstract

OBJECTIVES: To explore the relative and absolute risks associated with various definitions for myocardial infarction, bleeding and revascularisation within the context of percutaneous coronary intervention (PCI).
METHODS: The REPLACE-2 (randomised evaluation of PCI linking Angiomax to reduced clinical events) database of patients undergoing PCI was used. Various definitions of myocardial infarction, bleeding and revascularisation were modelled by logistic regression assessing their relationship with 12-month mortality. Estimates from these models were used to calculate the "attributable fraction" for late mortality associated with each definition.
RESULTS: The most liberal definition of myocardial infarction was associated with an attributable risk of 13.7% (95% CI 3.4% to 23.0%). The most stringent definition was associated with an attributable risk of 4.6% (95% CI 0.6% to 8.6%). Restrictive definitions of bleeding such as TIMI (thrombolysis in myocardial infarction) major bleeding are associated with a high odds ratio of risk (6.1, 95% CI 2.1 to 17.7, p = 0.001) but low attributable fraction (3.5%, 95% CI 0.9% to 6.8%).
CONCLUSIONS: Stringent end point definitions may under-represent the clinical significance of adverse outcomes after PCI. Considering both the proportional and absolute risk associated with definitions may be a more useful method for evaluating clinical trial end points. This analysis supports the current definitions of ischaemic events but suggests that more liberal definitions of bleeding events may also be relevant to late mortality.

Entities:  

Mesh:

Year:  2005        PMID: 16387822      PMCID: PMC1860685          DOI: 10.1136/hrt.2005.078758

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  17 in total

1.  Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality.

Authors:  Sorin J Brener; Bruce W Lytle; Jakob P Schneider; Stephen G Ellis; Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2002-12-04       Impact factor: 24.094

Review 2.  Methods of adjustment for estimating the attributable risk in case-control studies: a review.

Authors:  J Benichou
Journal:  Stat Med       Date:  1991-11       Impact factor: 2.373

Review 3.  The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures.

Authors:  A E Abdelmeguid; E J Topol
Journal:  Circulation       Date:  1996-12-15       Impact factor: 29.690

4.  Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

Authors:  A Michael Lincoff; John A Bittl; Robert A Harrington; Frederick Feit; Neal S Kleiman; J Daniel Jackman; Ian J Sarembock; David J Cohen; Douglas Spriggs; Ramin Ebrahimi; Gadi Keren; Jeffrey Carr; Eric A Cohen; Amadeo Betriu; Walter Desmet; Dean J Kereiakes; Wolfgang Rutsch; Robert G Wilcox; Pim J de Feyter; Alec Vahanian; Eric J Topol
Journal:  JAMA       Date:  2003-02-19       Impact factor: 56.272

5.  Prognostic implication of creatine kinase elevation following elective coronary artery interventions.

Authors:  T Q Kong; C J Davidson; S N Meyers; J T Tauke; M A Parker; R O Bonow
Journal:  JAMA       Date:  1997-02-12       Impact factor: 56.272

6.  Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions.

Authors:  Timothy D Kinnaird; Eugenio Stabile; Gary S Mintz; Cheol Whan Lee; Daniel A Canos; Natalie Gevorkian; Ellen E Pinnow; Kenneth M Kent; Augusto D Pichard; Lowell F Satler; Neil J Weissman; Joseph Lindsay; Shmuel Fuchs
Journal:  Am J Cardiol       Date:  2003-10-15       Impact factor: 2.778

7.  Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy.

Authors:  C S Landefeld; E F Cook; M Flatley; M Weisberg; L Goldman
Journal:  Am J Med       Date:  1987-04       Impact factor: 4.965

8.  Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures.

Authors:  Allen Jeremias; Donald S Baim; Kalon K L Ho; Manish Chauhan; Joseph P Carrozza; David J Cohen; Jeffrey J Popma; Richard E Kuntz; Donald E Cutlip
Journal:  J Am Coll Cardiol       Date:  2004-09-15       Impact factor: 24.094

9.  Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.

Authors:  A Michael Lincoff; Neal S Kleiman; Dean J Kereiakes; Frederick Feit; John A Bittl; J Daniel Jackman; Ian J Sarembock; David J Cohen; Douglas Spriggs; Ramin Ebrahimi; Gadi Keren; Jeffrey Carr; Eric A Cohen; Amadeo Betriu; Walter Desmet; Wolfgang Rutsch; Robert G Wilcox; Pim J de Feyter; Alec Vahanian; Eric J Topol
Journal:  JAMA       Date:  2004-08-11       Impact factor: 56.272

10.  Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.

Authors:  A K Rao; C Pratt; A Berke; A Jaffe; I Ockene; T L Schreiber; W R Bell; G Knatterud; T L Robertson; M L Terrin
Journal:  J Am Coll Cardiol       Date:  1988-01       Impact factor: 24.094

View more
  4 in total

1.  End points in clinical trials: are they moving the goalposts?

Authors:  D Y Leung; J K French
Journal:  Heart       Date:  2006-07       Impact factor: 5.994

2.  Measurement and prevention of myocardial injury during percutaneous coronary intervention.

Authors:  Patrick Schiano; Philippe Gabriel Steg
Journal:  Heart       Date:  2007-06       Impact factor: 5.994

3.  Factor XIIIA-V34L and factor XIIIB-H95R gene variants: effects on survival in myocardial infarction patients.

Authors:  Donato Gemmati; Federica Federici; Gianluca Campo; Silvia Tognazzo; Maria L Serino; Monica De Mattei; Marco Valgimigli; Patrizia Malagutti; Gabriele Guardigli; Paolo Ferraresi; Francesco Bernardi; Roberto Ferrari; Gian L Scapoli; Linda Catozzi
Journal:  Mol Med       Date:  2007 Jan-Feb       Impact factor: 6.354

4.  Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials.

Authors:  Christoph B Olivier; Vandana Sundaram; Deepak L Bhatt; Sergio Leonardi; Renato D Lopes; Victoria Y Ding; Lingyao Yang; Gregg W Stone; Ph Gabriel Steg; C Michael Gibson; Christian W Hamm; Matthew J Price; Harvey D White; Manisha Desai; Donald R Lynch; Robert A Harrington; Kenneth W Mahaffey
Journal:  Int J Cardiol       Date:  2018-06-08       Impact factor: 4.164

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.